Please login to the form below

secukinumab

This page shows the latest secukinumab news and features for those working in and with pharma, biotech and healthcare.

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

In a head-to-head challenge, J&J’s recently approved follow-up to Stelara (ustekinumab) – Tremfya (guselkumab) - was found to be superior to Cosentyx (secukinumab) in the treatment of adults

Latest news

Novartis buys cancer specialist Endocyte for $2.1bn

the back of gains for new psoriasis drug Cosentyx (secukinumab) and Entresto (sacubitril/valsartan) for heart failure – up 37% to $750m and 113% to $271m, respectively – as well as Sandoz’ biosimilar
Amgen’s R&D chief Sean Harper retires to seek biotech post

from biosimilars and newer drugs such as Novartis’ fast-growing IL-17 inhibitor Cosentyx (secukinumab).
Novartis follows Pfizer and freezes US prices this year

Novartis’ decision to keep pricing steady has been helped by a rosy set of second-quarter results, with recent launches Cosentyx (secukinumab) for psoriasis and heart failure therapy Entresto (sacubitril and
GSK sells eczema and psoriasis drug to Dermavant for £250m

In the case of psoriasis, that includes not only new therapies such as Novartis’ IL-17 inhibitor Cosentyx (secukinumab) and Johnson &Johnson’s IL-23/IL-12 inhibitor Tremfya (guselkumab), but
UK, Germany back routine use of J&J’s Tremfya

psoriasis therapies such as Novartis’ fast-growing IL-17 inhibitor Cosentyx (secukinumab), which EvaluatePharma expects to become a $4.6bn product by 2022.

More from news
Approximately 15 fully matching, plus 62 partially matching documents found.

Latest appointments

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

multiple sclerosis and secukinumab for several inflammatory conditions. .

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Great salary and benefits

Account Director, Medical Education: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Project Manager/ Account Manager: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Senior Medical Writer: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Digital Account Director: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Healthcare Marketing Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....